OpenAI buys Orchestra Bio to bring AI into drug development work
Why it matters
Biopharma teams now have OpenAI heading into their R&D operations, so reassess any AI workflow vendors you rely on.
Ask your team
Which of our R&D workflow tools overlap with what OpenAI and Orchestra Bio will offer?
What happened
OpenAI is buying Orchestra Bio, a company that applies AI to the day-to-day running of research and development in the life sciences. The aim is to help drug makers move treatments through development faster.
Tap an underlined word to see what it means.
Impact on Health
The context Last OpenAI story: OpenAI is training ChatGPT to handle old and rarely used coding languages (20 Oct) · 13 OpenAI stories in the last 30 days
Read the original at OpenAI News
Something wrong in this story? Report a mistake. We check it against the source within 24 hours.
Share with your take
Start from our line and make it yours. It stays on your device until you post it.
Ask about this story
Answered only from this story, with the line it came from.